Loading candles…
Bafna Pharmaceuticals Ltd, incorporated in 1981 and headquartered in Chennai, operates in the pharmaceutical industry. The company manufactures finished pharmaceutical formulations and offers therapeutic products along with Contract Research and Manufacturing Services (CRAMS). Its business segments include finished dosage formulations and CRAMS. Bafna Pharmaceuticals focuses on export markets, serving India and more than 20 countries globally, including both regulated and emerging markets. The company holds global regulatory approvals, notably from the UK-MHRA and TGA Australia.
This page is a live market overview for BAFNA PHARMACEUTICALS LTD (BAFNAPH) on the NSE. As a listed security, BAFNA PHARMACEUTICALS LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for BAFNAPH before placing trades on tick2trade.
As of the latest feed, BAFNAPH last traded at ₹336.5 on NSE, up ₹6.55 (1.99%) from the previous close of ₹329.95. Today's session range is ₹336.5 – ₹336.5, against a 52-week band of ₹94.77 – ₹336.5. Traded volume today stands at 21 shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for BAFNAPH in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether BAFNAPH is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for BAFNA PHARMACEUTICALS LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in BAFNAPH. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated BAFNAPH option chain page linked from this overview.
| Audited Results - Q4 & FY26 |
| To consider and approve the Audited Financial Results for the Quarter and Year ended March 31, 2026 |
| 29 May 2026 |
| Unaudited Results - Q3-FY25 | To consider and approve the Unaudited Financial Results for the Quarter ended December 31, 2025 | 11 Feb 2026 |
| Unaudited Results - Q2 & FY25 | To consider and approve the Un-audited financial results for the Quarter and Half Year ended September 30, 2025 | 11 Nov 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve the Un-audited Financial Results for the Quarter ended Jun 30, 2025 | 12 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the Audited Financial Results for the Quarter & Year ended March 31, 2025 | 26 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.